Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc. (SNDX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Syndax is a commercial-stage biopharmaceutical company focused on cancer therapies. It operates as a single segment with two FDA-approved products: Revuforj (revumenib) for acute leukemia and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease (cGVHD). The company co-commercializes Niktimvo with Incyte Corporation.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $64,864 | $20,042 |
| Product Revenue (Revuforj) | $48,923 | $20,042 |
| Collaboration Revenue (Niktimvo) | $15,941 | $0 |
| Net Loss | $(42,673) | $(84,846) |
| Loss Per Share (Basic & Diluted) | $(0.48) | $(0.98) |
| Cash, Cash Equivalents & Short-term Investments | $352,064 | $154,210 (End of Period Cash) |
| Net Cash Used in Operating Activities | $(50,345) | $(95,162) |
| Accumulated Deficit | $(1,549,253) | $(1,306,004) |
Debt & Liquidity: The company holds a significant Royalty Interest Financing Liability of approximately $344.0 million (net of issuance costs) related to a $350 million upfront payment received from Royalty Pharma in November 2024. This liability carries an effective interest rate of approximately 13.02%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 224% ($44.8 million) compared to Q1 2025. This was driven by a 144% increase in Revuforj product revenue and the recognition of $15.9 million in collaboration revenue from Niktimvo, which was not present in the prior year.
- Improved Loss Profile: Net loss decreased by 50% ($42.2 million) to $42.7 million, primarily due to the significant revenue increase and a reduction in operating expenses.
- Operating Expenses: Total operating expenses decreased by $4.7 million to $99.1 million.
- R&D: Decreased by $2.8 million, largely due to the absence of a non-recurring $10.0 million development milestone expense recognized in Q1 2025 for axatilimab.
- SG&A: Decreased by $3.4 million, driven by lower commercial launch costs compared to the prior year.
- Interest Expense: Royalty interest expense increased by $3.8 million to $11.8 million due to the accrual of interest on the Royalty Pharma financing arrangement.
Outlook, Risks, and Management Commentary
Management Commentary:
- Revuforj: Q1 2026 net revenue was $48.9 million, with total prescriptions up 160% year-over-year. Management notes that nearly half of KMT2A patients are proceeding to hematopoietic stem cell transplant (HSCT) after treatment, potentially extending treatment duration.
- Niktimvo: Generated $55.1 million in net revenue in Q1 2026. Syndax recognized $15.9 million in collaboration revenue (50% share of net profit).
- Clinical Pipeline: Multiple Phase 3 trials are ongoing for Revuforj (EVOLVE-2, REVEAL-ND) and Niktimvo. Topline data for several studies is expected in late 2026 and 2028.
Liquidity & Capital Resources:
- Management believes current cash, investments ($352.1 million), and expected product revenues are sufficient to fund operations for the foreseeable future.
- The company maintains an At-The-Market (ATM) offering program with $157.9 million remaining capacity as of March 31, 2026, though no shares were sold in Q1 2026.
Risks & Contingencies:
- Financing Obligations: The Royalty Pharma agreement requires payments capped at $822.5 million. Failure to meet sales projections could impact the effective interest rate and cash flow.
- Development Uncertainty: Future profitability depends on the success of ongoing clinical trials and regulatory approvals for new indications.
- Market Risks: Exposure to interest rate fluctuations and geopolitical instability affecting capital markets and supply chains.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of Revuforj prescriptions and the impact of the second FDA approval (NPM1m AML) on future sales.
- Royalty Financing Impact: Assess the cash flow implications of the $350 million Royalty Pharma liability and the 13.8% royalty rate on Niktimvo sales.
- Clinical Milestones: Monitor upcoming data readouts for Revuforj (EVOLVE-2, REVEAL-ND) and Niktimvo (Phase 3 cGVHD) scheduled for late 2026 and 2028.
- Burn Rate: Confirm that the reduction in operating cash burn ($50.3M in Q1 2026) is sustainable as the company scales commercial operations.
- Collaboration Terms: Review the profit-sharing mechanics with Incyte for Niktimvo to understand the volatility of collaboration revenue.